A catalyst precursor composition for forming a phenol alkylation catalyst, the composition comprising: 70 to 98 weight percent of abase oxide comprising: magnesium oxide with a Brunauer-Emmett-Teller surface area from 75 meter.sup.2/gram to 220 meter.sup.2/gram, preferably from 75 meter.sup.2/gram to 140 meter.sup.2/gram, more preferably from 90 meter.sup.2/gram to 130 meter.sup.2/gram; or magnesium carbonate with a Brunauer-Emmett-Teller surface area of from 100 meter.sup.2/gram to 220 meter.sup.2/gram, preferably from 120 meter.sup.2/gram to 200 meter.sup.2/gram; or a combination thereof; at least one metal promoter precursor comprising an iron precursor, a manganese, a vanadium precursor, or a copper precursor; and a pore former, a lubricant, a coke inhibitor; and optionally, a strength additive; and optionally a binder, and a method of alkylating phenol using a catalyst derived from the catalyst precursor.

A catalyst precursor composition for forming a phenol alkylation catalyst, the composition comprising: 70 to 98 weight percent of abase oxide comprising: magnesium oxide with a Brunauer-Emmett-Teller surface area from 75 meter.sup.2/gram to 220 meter.sup.2/gram, preferably from 75 meter.sup.2/gram to 140 meter.sup.2/gram, more preferably from 90 meter.sup.2/gram to 130 meter.sup.2/gram; or magnesium carbonate with a Brunauer-Emmett-Teller surface area of from 100 meter.sup.2/gram to 220 meter.sup.2/gram, preferably from 120 meter.sup.2/gram to 200 meter.sup.2/gram; or a combination thereof; at least one metal promoter precursor comprising an iron precursor, a manganese, a vanadium precursor, or a copper precursor; and a pore former, a lubricant, a coke inhibitor; and optionally, a strength additive; and optionally a binder, and a method of alkylating phenol using a catalyst derived from the catalyst precursor.

The disclosure provides processes for synthesizing compounds for use as CFTR modulators. ##STR00001##

The disclosure provides processes for synthesizing compounds for use as CFTR modulators. ##STR00001##

The present disclosure relates to new cannabinoid derivatives and precursors and processes for their preparation. The disclosure also relates to pharmaceutical and analytical uses of the new cannabinoid derivatives.

The present disclosure relates to new cannabinoid derivatives and precursors and processes for their preparation. The disclosure also relates to pharmaceutical and analytical uses of the new cannabinoid derivatives.

Cannabidiol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, prodrugs, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description

##STR00001##

Cannabidiol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, prodrugs, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description

##STR00001##

Disclosed are methods for preparing cannabigerol (CBG) or a CBG analog, embodiments of the method comprising providing a compound (I); combining the compound (I) with geraniol and a solvent to form a reaction mixture; and combining the reaction mixture with an acid catalyst to form a product mixture comprising the CBG or the CBG homolog. The method may further comprise separating the CBG or the CBG analog from the product mixture and may further comprise purifying the CBG or CBG analog. Methods for preparing cannabigerolic acid (CBGA) or a cannabigerolic acid analog are also disclosed. The present disclosure also provides highly purity CBG, CBGA, and analogs thereof.

Disclosed are methods for preparing cannabigerol (CBG) or a CBG analog, embodiments of the method comprising providing a compound (I); combining the compound (I) with geraniol and a solvent to form a reaction mixture; and combining the reaction mixture with an acid catalyst to form a product mixture comprising the CBG or the CBG homolog. The method may further comprise separating the CBG or the CBG analog from the product mixture and may further comprise purifying the CBG or CBG analog. Methods for preparing cannabigerolic acid (CBGA) or a cannabigerolic acid analog are also disclosed. The present disclosure also provides highly purity CBG, CBGA, and analogs thereof.